FDA Guidance and Notices, March 2025: Sex-Specific Data in Device Clinical Studies and a Recognized Standards Update
Two things happened on March 31, 2025. FDA issued final guidance on evaluating sex-specific data in medical device clinical studies, and a federal district court vacated FDA's 2024 final rule on laboratory developed tests (LDTs). FDA later issued a final rule on September 19, 2025, returning to the earlier provisions.
If you rely on declarations of conformity, look at the March 20 Federal Register notice updating the list of recognized consensus standards (Recognition List 063). On March 14, FDA wrote to health care providers about a shortage of hemodialysis bloodlines.
Final guidance
- Data Standards Catalog (March 24): Lists the data standards used in electronic submissions to FDA. It is posted as a Level 2 guidance.
- Evaluation of Sex-Specific Data in Medical Device Clinical Studies (March 31): Sets out how FDA expects sex-specific data from device clinical studies to be evaluated.
In the Federal Register
- Food and Drug Administration Modernization Act of 1997: Modifications to the List of Recognized Standards, Recognition List Number: 063 (March 20): Adds, modifies and withdraws standards FDA recognizes for premarket review. If you use a declaration of conformity, check each standard's scope of recognition and transition period in the notice and the recognized standards database.
Safety communications and other updates
- Disruptions in Availability of Hemodialysis Bloodlines - Letter to Health Care Providers (March 14): Supplier problems have caused a shortage. FDA recommends that providers monitor inventory, conserve supplies and voluntarily report shortages to the agency.
- MDUFA Workforce Metrics Assessment (date not confirmed): An independent review of how FDA measures and reports staffing under the Medical Device User Fee Amendments (MDUFA), with recommendations on definitions, consolidated reporting and governance.
Also this month
- March 31: A federal district court vacated FDA's 2024 final rule on LDTs.
Note: dates are FDA issue dates or Federal Register publication dates. Linked pages may now show a later version.
RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.
← All articles